STV Analysis Versus Visual Evaluation of Cardiotocography in FGR

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-99
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

About this trial

This stepped wedge cluster randomized clinical trial investigates whether in pregnant women with severe, early-onset fetal growth restriction, the use of STV analysis in fetal monitoring improves the chances of perinatal survival, compared with visual evaluation of the cardiotocography.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pregnant women with a singleton pregnancy between 24 weeks and 0 days and 31 weeks and 6 days with severe, early-onset fetal growth restriction, admitted in hospital or frequently evaluated ambulatory by CTG (according to local protocol) for fetal monitoring.

Fetal growth restriction is defined in line with the international Delphi consensus as biometric ultrasound measurement of the abdominal circumference (AC) OR a combination of measurements resulting in an estimated fetal weight (EFW) below the 3rd percentile (<p3) OR a combination of EFW <p10 AND uterine artery pulsatility index (PI) >p95 OR umbilical artery Doppler PI >p95.

Maternal age ≥ 18 years.

Able to provide written informed consent for collection and use of data on informed consent form in available language.

Disqualifiers

Known congenital or chromosomal anomalies influencing perinatal outcome.

Imminent labour or expected maternal indication for delivery < 48 hours.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Short term variation

    Device

    Short term variation in computer software analysis

  • Visual interpretation

    Device

    Visual interpretation of cardiotocography

Treatment groups

800 Participants
are divided into 2 treatment groups
Group A: Visual interpretation of cardiotocographyActive comparator 1 intervention
Group B: Short term variationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Proportion of pregnancies resulting in perinatal death

Perinatal death is defined as antenatal death or neonatal/infant death before discharge from NICU

Time frame
Before discharge from neonatal intensive care unit (NICU), up to 1 year

Secondary outcomes

1

Proportion of children with major neonatal morbidity

Major neonatal morbidity is a composite outcome defined as intraventricular hemorrhage grade 3 or more, periventricular leukomalacia grade 2 or more, moderate or severe bronchopulmonary dysplasia, necrotizing enterocolitis Bell stage 2 or more, or retinopathy of prematurity requiring therapy.

Time frame
Before discharge from NICU, up to 1 year
2

Proportion of children with neonatal morbidities

Individual neonatal morbidities of the abovementioned composite outcome and additionally persisting ductus arteriosus, persistent pulmonary hypertension of the newborn (PPHN), respiratory distress syndrome (RDS), period of invasive mechanical ventilation in days, medication need, hypoglycaemia, neonatal jaundice, sepsis and cardiovascular function.

Time frame
Before discharge from NICU, up to 1 year
3

Proportion of children with neurodevelopmental impairment

Neurodevelopmental impairment is defined as an abnormal test on Bayley III Dutch version (or version IV if available) (composite cognitive score \< 85, composite motor score \< 85), cerebral palsy, with a Gross Motor Function Classification System (GMFCS) grade \> 1, hearing loss needing hearing aids, or severe visual loss (legally certifiable as blind or partially sighted) assessed at two years of corrected age

Time frame
At two years of corrected age

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: